ESMO 2018

Area: Oncology

Location: Munich, Germany

Date: October 19 to October 23

Description:

Annual Congress of the European Society for Medical Oncology.


Search in Scientific Content:
Date
Filters:
Biomarkers
9:23

Biomarkers in immuno-oncology

Presenter: Manfred Dietel
Oncology
First-Line
3:53

First-Line Pembrolizumab for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma: Interim Results From the Phase 3 KEYNOTE-048 Study

Presenter: Barbara Burtness
Oncology
Updates on
4:58

Updates on NETs and endocrine tumours

Presenter: Enrique Grande
Oncology
Clinical i
7:54

Clinical implementation of PI3K inhibitors

Presenter: Evandro de Azambuja
Oncology
Targeted t
6:17

Targeted therapy and EGFR mutations

Presenter: Benjamin Besse
Oncology
Highlitghs
8:30

Highlitghs of ESMO - IO and targeted therapy in lung cancer

Presenter: Solange Peters
Oncology
Two illust
10:33

Two illustrative and interactive tumour board style case study discussions

Presenter: Christine Brezden-Masley
Oncology
Update on
2:29

Update on the latest clinical practice referring to NETs

Presenter: Angela Lamarca
Oncology
New result
4:36

New results in Head and Neck Cancer

Presenter: Jean-Pascal Machiels
Oncology
Biomarkes
5:59

Biomarkes in Immuno-Oncology (PDL-1 testing)

Presenter: Federico Cappuzzo
Oncology
How to man...
4:03

How to manage pretreated mCRC patients: An expert’s approach

Presenter: Julien Taieb
Oncology
IMpassion1
2:46

IMpassion130: Results from a global, randomised, double-blind, phase 3 study of atezolizumab + nab-paclitaxel vs placebo + nab-P in treatment-naive, locally advanced or metastatic triple-negative breast cancer IMPassion130

Presenter: Peter Schmid
Oncology
Overall su
3:56

Overall survival with palbociclib plus fulvestrant in women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: Analyses from PALOMA-3

Presenter: Massimo Cristofanilli
Oncology
Alpelisib
3:20

Alpelisib + fulvestrant for advanced breast cancer: results of the Phase III SOLAR-1 trial

Presenter: Fabrice André
Oncology
IMpassion1
1:24

IMpassion130: Results from a global, randomised, double-blind, phase 3 study of atezolizumab + nab-paclitaxel vs placebo + nab-P in treatment-naive, locally advanced or metastatic triple-negative breast cancer IMPassion130

Presenter: Giuseppe Curigliano
Oncology
Use of imm...
7:40

Use of immune checkpoint inhibitors in early stage NSCLC – Next generation trials in NSCLC

Presenter: Giorgio Scagliotti
Oncology

ASCO 2015

2015-05-29 - 2015-06-02
Chicago, United States

ELCC 2015

2015-04-15 - 2015-04-18
Geneva, Switzerland

Bratislava 2014

2014-10-09 - 2014-10-10
Bratislava, Slovakia

ESMO 2014

2014-09-26 - 2014-09-30
Madrid, Spain